UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | K | L | M | P | R
Number of items: 17.

A

Ainley, L; Chavda, SJ; Counsell, N; Cheesman, S; Newrick, F; Horder, J; Kyriakou, C; ... Yong, K; + view all (2021) DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation. British Journal of Haematology , 192 (3) e73-e77. 10.1111/bjh.17248.

Arend, RC; Monk, BJ; Herzog, TJ; Moore, KN; Shapira-Frommer, R; Ledermann, JA; Tewari, KS; ... Penson, RT; + view all (2021) Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer. Gynecologic Oncology 10.1016/j.ygyno.2021.02.014. (In press).

B

Baert, T; Ferrero, A; Sehouli, J; O Donnell, DM; González-Martín, A; Joly, F; Van der Velden, J; ... Ledermann, JA; + view all (2021) The systemic treatment of recurrent ovarian cancer revisited. Annals of Oncology 10.1016/j.annonc.2021.02.015. (In press).

C

Camilleri, M; Cuadrado, M; Phillips, E; Wilson, W; Jenner, R; Pang, G; Kamora, S; ... Yong, K; + view all (2021) Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. British Journal of Haematology 10.1111/bjh.17377. (In press). Green open access
file

Camilleri, M; Sive, J; Wilson, W; Pang, G; Jenner, R; Phillips, E; Popat, R; ... Yong, K; + view all (2021) COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial. British Journal of Haematology , 192 (1) E14-E16. 10.1111/bjh.17168.

Concin, N; Creutzberg, CL; Vergote, I; Cibula, D; Mirza, MR; Marnitz, S; Ledermann, JA; ... Matias-Guiu, X; + view all (2021) ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv , 478 pp. 153-190. 10.1007/s00428-020-03007-z.

Concin, N; Matias-Guiu, X; Vergote, I; Cibula, D; Mirza, MR; Marnitz, S; Ledermann, J; ... Creutzberg, CL; + view all (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal Of Gynecological Cancer , 31 (1) pp. 12-39. 10.1136/ijgc-2020-002230. Green open access
file

Concin, N; Matias-Guiu, X; Vergote, I; Cibula, D; Mirza, MR; Marnitz, S; Ledermann, J; ... Creutzberg, CL; + view all (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiotherapy and Oncology , 154 pp. 327-353. 10.1016/j.radonc.2020.11.018.

Cross, AJ; Myles, J; Greliak, P; Hackshaw, A; Halloran, S; Benton, SC; Addison, C; ... Raine, R; + view all (2021) Including a general practice endorsement letter with the testing kit in the Bowel Cancer Screening Programme: Results of a cluster randomised trial. Journal of Medical Screening 10.1177/0969141321997480. Green open access
file

D

Dettorre, GM; Dolly, S; Loizidou, A; Chester, J; Jackson, A; Mukherjee, U; Zambelli, A; ... OnCovid study group, ; + view all (2021) Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. Journal for ImmunoTherapy of Cancer , 9 (3) , Article e002277. 10.1136/jitc-2020-002277. Green open access
file

K

Kurtz, JE; Gebski, V; Sukhin, V; Carey, M; Kong, I; Glasspool, RM; Berek, JS; ... Friedlander, M; + view all (2021) Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Gynecologic Oncology 10.1016/j.ygyno.2021.02.018. (In press).

L

Ledermann, JA; Embleton-Thirsk, AC; Perren, TJ; Jayson, GC; Rustin, GJS; Kaye, SB; Hirte, H; ... ICON6 collaborators, .; + view all (2021) Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. ESMO Open , 6 (2) , Article 100043. 10.1016/j.esmoop.2020.100043. Green open access
file

Lee, CK; Friedlander, ML; Tjokrowidjaja, A; Ledermann, JA; Coleman, RL; Mirza, MR; Matulonis, UA; ... Scott, CL; + view all (2021) Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Cancer 10.1002/cncr.33517. (In press).

M

McCulloch, R; Lewis, D; Crosbie, N; Eyre, TA; Bolam, S; Arasaretnam, A; Creasey, T; ... Rule, S; + view all (2021) Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. British Journal of Haematology 10.1111/bjh.17363. Green open access
file

P

Popat, R; Counsell, N; de Tute, R; De-Silva, D; Phillips, EH; Cavenagh, JD; Adedayo, T; ... Yong, K; + view all (2021) Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial. British Journal of Haematology 10.1111/bjh.17391. (In press).

Poveda, A; Floquet, A; Ledermann, JA; Asher, R; Penson, RT; Oza, AM; Korach, J; ... SOLO2/ENGOT-Ov21 investigators, .; + view all (2021) Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology 10.1016/S1470-2045(21)00073-5. (In press).

R

Russell, J; Collins, A; Fowler, A; Karanth, M; Saha, C; Docherty, S; Padayatty, J; ... Follows, GA; + view all (2021) Advanced Hodgkin lymphoma in the East of England: a 10-year comparative analysis of outcomes for real-world patients treated with ABVD or escalated-BEACOPP, aged less than 60 years, compared with 5-year extended follow-up from the RATHL trial. Annals of Hematology , 100 pp. 1049-1058. 10.1007/s00277-021-04460-9. Green open access
file

This list was generated on Thu Apr 22 11:48:03 2021 BST.